| 2017 |
Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tiss Int. October 2017;101(4):371-374. |
16 |
16 |
| 2020 |
Reid IR, Horne AM, Mihov B, Stewart A, Bastin S, Gamble GD. Zoledronate slows weight loss and maintains fat mass in osteopenic older women: secondary analysis of a randomized controlled trial. Calcif Tiss Int. April 2020;106(4):386-391. |
1 |
0 |
| 2020 |
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. January 2020;35(1):20-27. |
11 |
11 |
| 2021 |
Reid IR, Horne AM, Mihov B, Stewart A, Bolland MJ, Bastin S, Gamble GD. Predictors of fracture in older women with osteopenic hip bone mineral density treated with zoledronate. J Bone Miner Res. January 2021;36(1):61-66. |
0 |
0 |
| 2022 |
Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Bone mineral density and bone turnover 10 years after a single 5 mg dose or two 5-yearly lower doses of zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial. J Bone Miner Res. January 2022;37(1):3-11. |
1 |
0 |
| 2022 |
Reid IR, Bastin S, Horne AM, Mihov B, Gamble GD, Bolland MJ. Zoledronate reduces height loss independently of vertebral fracture occurrence in a randomized trial in osteopenic older women. J Bone Miner Res. November 2022;37(11):2149-2155. |
0 |
0 |
| 2023 |
Reid IR, Horne AM, Mihov B, Bastin S, Gamble GD. No effect of NSAID use on efficacy of zoledronate: a post hoc analysis of a randomized trial in osteopenic older women. J Bone Miner Res. October 2023;38(10):1415-1421. |
0 |
0 |
| 2018 |
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. NEJM. December 20, 2018;379(25):2407-2416. |
45 |
36 |